New diabetes clinical trial: Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

Published on: July 12, 2019 at 07:00PM
Conditions:   Diabetes Mellitus, Type 2;   Urosepsis;   Diabetic Ketoacidosis;   Lower Extremity Amputation
Interventions:   Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors;   Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors;   Drug: Other treatment combinations
Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting